Androgen Regulation of Gene Expression in Human Meibomian Gland and Conjunctival Epithelial Cells

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10381376

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Androgen regulation of gene expression in human meibomian gland and conjunctival epithelial cells

Payal Khandelwal, Shaohui Liu, David A. Sullivan

Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, MA

Purpose: Androgens exert a significant influence on the structure, function and/or pathophysiology of the meibomian gland and conjunctiva. We sought to determine whether this hormone action involves the regulation of epithelial cell gene expression in these tissues.

Methods: Immortalized human meibomian gland and conjunctival epithelial cells were treated with placebo or dihydrotestosterone (DHT) and processed for molecular biologic procedures. Gene expression was evaluated with BeadChips and data were analyzed with bioinformatic and statistical software.

Results: Androgen treatment significantly influenced the expression of approximately 3,000 genes in immortalized human meibomian gland and conjunctival epithelial cells. The nature of DHT action on gene activity was predominantly cell-specific. Similarly, DHT exerted a significant, but primarily cell-specific, influence on many gene ontologies and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. These included groups of genes related, for example, to lipid dynamics, innate immunity, cell cycle, Janus kinase (JAK)-signal transducer and activator of transcription (stat) cascades, oxidative phosphorylation, the proteasome, and mammalian target of rapamycin (mTOR), Wnt, and peroxisome proliferator-activated receptor (PPAR) signaling.

Conclusions: Our findings support our hypothesis that androgens regulate gene expression in human meibomian gland and conjunctival epithelial cells. Our ongoing studies are designed to determine whether many of these genes are translated and play a role in the health and well being of the eye.

Androgens exert a significant influence on the structure, function and/or pathophysiology of many ocular tissues, including the meibomian gland, lacrimal gland, conjunctiva, and cornea [1-12]. These hormones regulate such ocular parameters as glandular architecture, protein synthesis and secretion, meibum production, mucus expression, aqueous tear output, tear film stability, immune activity, and epithelial cell dynamics [1-12]. Androgens have also been reported to correct defects, facilitate wound healing [6,7,13], suppress angiogenesis [14], and stimulate mitosis [9] in the corneal epithelium, to alter the development of allergic conjunctivitis [5], and to attenuate inflammation in autoimmune lacrimal tissue [8,11]. In addition, androgens have been proposed as a topical therapy for the treatment of aqueous-deficient and evaporative dry eye diseases [8,11]. However, despite these observations, the precise mechanisms underlying androgen-eye interactions in humans remain to be clarified.

We hypothesize that androgen action on the eye involves the local, intracrine synthesis of this sex steroid from adrenal precursors (e.g., dehydroepiandrosterone), binding to saturable, high-affinity and androgen-specific receptors, control of gene transcription, and ultimately modulation of translation. In support of this hypothesis, we have discovered that the human meibomian and lacrimal glands, and immortalized corneal and conjunctival epithelial cells, contain all the steroidogenic enzyme mRNAs necessary for the intracrine synthesis and metabolism of androgens [15]. Moreover, we have shown that androgen receptor mRNA and protein are present in epithelial cell nuclei of the human meibomian and lacrimal glands, cornea and conjunctiva [16,17].

To continue to test our hypothesis, we examined the influence of androgens in gene expression in immortalized human meibomian gland and conjunctival epithelial cells.

METHODS

Cell culture and hormone treatment: Immortalized human meibomian gland epithelial cells, which were recently generated in our laboratory [2], were cultured in Keratinocyte Serum-Free Medium [KSFM] supplemented with 50 μg/ml bovine pituitary extract (BPE), 5 ng/ml epidermal growth factor (EGF), and 100 U penicillin-streptomycin (Invitrogen, Carlsbad, CA). Cells were incubated in a humidified, 37 °C chamber under 5% CO2/95% air. Immortalized human conjunctival epithelial cells, which were gifted by Dr. Ilene Gipson (Boston, MA), were cultured in serum-free conditions as previously described [18].

When approximately 80% confluent, cells were exposed to 10 nM dihydrotestosterone (DHT; Steraloids, Wilton, NH) or placebo for 3 (meibomian) or 4 (conjunctiva) days. These


**Table 1. Influence of DHT on Gene Expression in Human Meibomian Gland and Conjunctival Epithelial Cells.**

<table>
<thead>
<tr>
<th>Immortalized human epithelial cell type</th>
<th>DHT→Placebo</th>
<th>Placebo→DHT</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meibomian gland</td>
<td>1,485</td>
<td>1,494</td>
<td>2,979</td>
</tr>
<tr>
<td>Conjunctiva</td>
<td>1,350</td>
<td>1,662</td>
<td>3,012</td>
</tr>
</tbody>
</table>

Gene expression was significantly (p<0.05) upregulated in cells exposed to DHT or placebo treatment, as shown by the analysis of log-transformed data.

time periods were previously shown to be optimal for the generation of DHT-induced alterations in androgen receptor mRNA levels in the different cell types [19]. For these studies the DHT was dissolved in ethanol and aliquots were evaporated in sterilized vials before the addition of medium. The placebo was prepared by transferring media to vials containing the residue of evaporated ethanol. After hormone treatment, cells were harvested and processed for RNA isolation.

Molecular biologic procedures: Total RNA was extracted with RNAqueous Kits (Ambion, Austin, TX) and evaluated on a RNA Nano 6000 Series II Chip with a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) to confirm RNA integrity. The RNA concentrations and associated 260/280 nm ratios were determined using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Waltham MA).

The RNA (100 ng) samples were processed by Asuragen (Austin, TX) for the determination of mRNA levels by using Illumina HumanHT-12 v3 Expression BeadChips (San Diego, CA). These BeadChips target more than 25,000 annotated genes with over 48,000 probes derived from NCBI reference sequences and the UniGene databases. In brief, biotin-labeled cRNA samples were generated by using a MessageAmp™ II-based protocol (Ambion Inc., Austin, TX), quantitated by UV spectrophotometry and analyzed with an Agilent 2100 Bioanalyzer capillary electrophoresis system. The labeled cRNAs were used to probe the BeadChips. Hybridization, washing, and scanning of the Illumina arrays were conducted according to the manufacturer’s instructions. Data were processed with Illumina BeadStudio software v3 by using both background subtraction and cubic spline normalization. Standardized hybridization intensity values were adjusted by adding a constant, so that the lowest intensity value for any sample equaled 16 [20].

Normalized data were analyzed with GeneSifter.Net software (Geospiza, Seattle, WA), a comprehensive program that also produced gene ontology and z-score reports. Ontologies included biologic processes, molecular functions and cellular components and were organized according to the guidelines of the Gene Ontology Consortium (GO) [21]. Gene expression data were analyzed with and without log transformation and statistical analyses of these data were performed with Student’s t-test (two-tailed, unpaired). Genes that were up- or down-regulated in the same direction in different experiments were identified by using the GeneSifter.Net intersector program (Geospiza). All data from the Illumina BeadChips are accessible for download through the National Center for Biotechnology Information’s Gene Expression Omnibus (GEO) via series accession numbers (GSE18091 and GSE18094).

Real time PCR procedures: The differential expression of selected genes was verified by using quantitative real-time PCR (qPCR) procedures. The cDNAs were transcribed by employing SuperScript III Reverse Transcriptase (Invitrogen, Grand Island, NY) and random hexamer primers (Invitrogen). The qPCR reactions were performed in triplicate by using TaqMan Gene Assays (Applied Biosystems, Inc., Foster City, CA) and TaqMan-specific primers and probes for aldo-keto reductase family 1, member c2 (Hs00413886_m1*), cdc28 protein kinase regulatory subunit 2 (Hs00244575_m1*), interferon α-inducible proteins 6 (Hs00242571_m1*), kallikrein related peptidase 11 (Hs01100849_m1*), keratin 16 (Hs00373910_g1*), laminin, α3 (Hs00165042_m1*), leupaxin (Hs0183105_m1*), minichromosome maintenance component 3 (Hs00172459_m1*), myosin light chain 6 (Hs00819642_m1; conjunctival epithelial cell endogenous control), n (α) acetyltransferase 50 (Hs00363889_m1*; meibomian gland epithelial cell endogenous control), plasminogen activator, urokinase (Hs00170182_m1), serum amyloid A1 (Hs00761940_s1), and uridine phosphorylase 1 (Hs00427695_m1*). Differential gene expression was calculated according to the Comparative Ct method, as outlined in Applied Biosystems User Bulletin 2 (updated 2001).

**RESULTS**

Androgen impact on gene expression in human ocular surface and meibomian gland epithelial cells: To determine the effect of DHT on gene expression in immortalized human meibomian gland and conjunctival epithelial cells, cells were exposed to placebo or DHT and processed for analysis by using Illumina BeadChips and Geospiza software. Our results demonstrate that DHT had a significant impact on the expression of approximately 3,000 genes in immortalized human meibomian gland and conjunctival epithelial cells (Table 1). The relative direction of this
### Table 2. Effect of DHT on Gene Expression Ratios in Immortalized Human Meibomian Gland Epithelial Cells.

<table>
<thead>
<tr>
<th>Accession #</th>
<th>Gene</th>
<th>Ratio</th>
<th>p value</th>
<th>Ontology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DHT&gt;Placebo</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NM_001001552</td>
<td>LEM domain containing 1</td>
<td>10.1</td>
<td>0.00000</td>
<td>nuclear envelope</td>
</tr>
<tr>
<td>NM_032563</td>
<td>Late cornified envelope 3D</td>
<td>4.5</td>
<td>0.00024</td>
<td>keratinization</td>
</tr>
<tr>
<td>NM_152565</td>
<td>ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d2</td>
<td>3.7</td>
<td>0.00048</td>
<td>ion transport</td>
</tr>
<tr>
<td>NM_021244</td>
<td>Ras-related GTP binding D</td>
<td>3.5</td>
<td>0.00010</td>
<td>positive regulation of TOR signaling cascade</td>
</tr>
<tr>
<td>NM_001031615</td>
<td>Aldehyde dehydrogenase 3 family, member B2</td>
<td>3.0</td>
<td>0.00004</td>
<td>alcohol metabolic process</td>
</tr>
<tr>
<td>NM_000435</td>
<td>Notch homolog 3</td>
<td>2.9</td>
<td>0.00015</td>
<td>regulation of transcription, DNA-dependent</td>
</tr>
<tr>
<td>NM_005218</td>
<td>Defensin, β1</td>
<td>2.6</td>
<td>0.00001</td>
<td>chemotaxis</td>
</tr>
<tr>
<td>NM_001003679</td>
<td>Leptin receptor</td>
<td>2.5</td>
<td>0.00553</td>
<td>energy reserve metabolic process</td>
</tr>
<tr>
<td>NM_001047</td>
<td>Steroid-5α-reductase, α polypeptide 1</td>
<td>1.9</td>
<td>0.00097</td>
<td>androgen biosynthetic process</td>
</tr>
<tr>
<td>NM_005063</td>
<td>Stearoyl-CoA desaturase</td>
<td>1.7</td>
<td>0.00039</td>
<td>fatty acid biosynthetic process</td>
</tr>
<tr>
<td>NM_002015</td>
<td>Forkhead box O1</td>
<td>1.6</td>
<td>0.00006</td>
<td>blood vessel development</td>
</tr>
<tr>
<td><strong>Placebo&gt;DHT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NM_181800</td>
<td>Ubiquitin-conjugating enzyme E2C</td>
<td>24.4</td>
<td>0.00000</td>
<td>cell cycle checkpoint</td>
</tr>
<tr>
<td>NM_001067</td>
<td>Topoisomerase (DNA) H α 170 kDa</td>
<td>16.7</td>
<td>0.00000</td>
<td>resolution of meiotic recombination</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>intermediates</td>
</tr>
<tr>
<td>NM_018454</td>
<td>Nucleolar and spindle associated protein 1</td>
<td>15.6</td>
<td>0.00006</td>
<td>mitotic sister chromatid segregation</td>
</tr>
<tr>
<td>NM_001255</td>
<td>Cell division cycle 20 homolog</td>
<td>13.4</td>
<td>0.00001</td>
<td>cell cycle checkpoint</td>
</tr>
<tr>
<td>NM_001786</td>
<td>Cyclin-dependent kinase 1</td>
<td>12.3</td>
<td>0.00000</td>
<td>cell cycle checkpoint</td>
</tr>
<tr>
<td>NM_001168</td>
<td>Baculoviral IAP repeat-containing 5</td>
<td>10.2</td>
<td>0.00000</td>
<td>cell cycle checkpoint</td>
</tr>
<tr>
<td>NM_004701</td>
<td>Cyclin B2</td>
<td>9.5</td>
<td>0.00002</td>
<td>G2/M transition of mitotic cell cycle</td>
</tr>
<tr>
<td>NM_002263</td>
<td>Kinesin family member C1</td>
<td>9.0</td>
<td>0.00000</td>
<td>cell cycle checkpoint</td>
</tr>
<tr>
<td>NM_002994</td>
<td>Chemokine (C-X-C motif) ligand 5</td>
<td>8.9</td>
<td>0.00019</td>
<td>mitotic sister chromatid segregation</td>
</tr>
<tr>
<td>NM_003246</td>
<td>Thrombospondin 1</td>
<td>4.7</td>
<td>0.00001</td>
<td>chemotaxis</td>
</tr>
<tr>
<td>NM_002727</td>
<td>Serglycin</td>
<td>2.5</td>
<td>0.00012</td>
<td>apoptosis</td>
</tr>
<tr>
<td>NM_004994</td>
<td>Matrix metallopeptidase 9</td>
<td>1.7</td>
<td>0.00001</td>
<td>proteolysis</td>
</tr>
</tbody>
</table>

Relative ratios were calculated by comparing the degree of gene expression in meibomian gland epithelial cells treated with placebo or DHT. The mean gene intensity level in at least one group exceeded 100 BeadChip units.
<table>
<thead>
<tr>
<th>Accession #</th>
<th>Gene</th>
<th>Ratio</th>
<th>p value</th>
<th>Ontology</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHT&gt;Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NM_004994</td>
<td>Matrix metallopeptidase 9</td>
<td>10.9</td>
<td>0.00000</td>
<td>proteolysis</td>
</tr>
<tr>
<td>NM_001012964</td>
<td>Kallikrein-related peptidase 6</td>
<td>10.5</td>
<td>0.00001</td>
<td>proteolysis</td>
</tr>
<tr>
<td>NM_001323</td>
<td>Cystatin E/M</td>
<td>10.4</td>
<td>0.00002</td>
<td>epidermis development</td>
</tr>
<tr>
<td>NM_003856</td>
<td>Interleukin 1 receptor-like 1</td>
<td>9.0</td>
<td>0.00006</td>
<td>immune response</td>
</tr>
<tr>
<td>NM_018043</td>
<td>Anoctamin 1, calcium activated chloride channel</td>
<td>8.0</td>
<td>0.00001</td>
<td>ion transport</td>
</tr>
<tr>
<td>NM_002153</td>
<td>Hydroxysteroid (17β) dehydrogenase 2</td>
<td>7.8</td>
<td>0.00000</td>
<td>steroid biosynthetic process</td>
</tr>
<tr>
<td>NM_005416</td>
<td>Small proline-rich protein 3</td>
<td>7.4</td>
<td>0.00023</td>
<td>epidermis development</td>
</tr>
<tr>
<td>NM_144947</td>
<td>Kallikrein-related peptidase 11</td>
<td>7.2</td>
<td>0.00003</td>
<td>proteolysis</td>
</tr>
<tr>
<td>NM_001077491</td>
<td>Kallikrein-related peptidase 5</td>
<td>7.1</td>
<td>0.00018</td>
<td>proteolysis</td>
</tr>
<tr>
<td>NM_198129</td>
<td>Laminin, α3</td>
<td>5.6</td>
<td>0.00001</td>
<td>epidermis development</td>
</tr>
<tr>
<td>Placebo &gt; DHT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NM_002993</td>
<td>Chemokine (C-X-C motif) ligand 6</td>
<td>12.4</td>
<td>0.00005</td>
<td>chemotaxis</td>
</tr>
<tr>
<td>NM_003186</td>
<td>Transgelin</td>
<td>10.8</td>
<td>0.0013</td>
<td>muscle organ development</td>
</tr>
<tr>
<td>NM_002974</td>
<td>Serpin peptidase inhibitor, clade B, member 4</td>
<td>10.1</td>
<td>0.00000</td>
<td>immune response</td>
</tr>
<tr>
<td>NM_001733</td>
<td>Complement component 1, r subcomponent</td>
<td>9.4</td>
<td>0.0012</td>
<td>proteolysis</td>
</tr>
<tr>
<td>NM_005602</td>
<td>Claudin 11</td>
<td>8.8</td>
<td>0.00005</td>
<td>cell adhesion</td>
</tr>
<tr>
<td>NM_006820</td>
<td>Interferon-induced protein 44-like</td>
<td>8.5</td>
<td>0.00001</td>
<td>immune response</td>
</tr>
<tr>
<td>NM_016352</td>
<td>Carboxypeptidase A4</td>
<td>8.4</td>
<td>0.00033</td>
<td>proteolysis</td>
</tr>
<tr>
<td>NM_003641</td>
<td>Interferon induced transmembrane protein 1</td>
<td>8.0</td>
<td>0.00001</td>
<td>cell surface receptor linked signaling pathway</td>
</tr>
<tr>
<td>NM_001710</td>
<td>Complement factor B</td>
<td>7.7</td>
<td>0.00000</td>
<td>proteolysis</td>
</tr>
<tr>
<td>NM_001044391</td>
<td>Mucin 1, cell surface associated</td>
<td>3.1</td>
<td>0.00127</td>
<td>protein binding</td>
</tr>
</tbody>
</table>

Relative ratios were determined by comparing the degree of gene expression in conjunctival epithelial cells treated with placebo or DHT. The mean gene intensity level in at least one group was higher than 100 BeadChip units.
The hormone effect was about the same in both cell types, with DHT up- and down-regulating similar percentages of genes (i.e., meibomian: 49.8% ↑; conjunctiva: 44.8% ↑). Examples of genes that showed notable hormone-induced differences in terms of ratios are listed in Table 2 and Table 3. In addition, DHT significantly enhanced the expression of genes encoding mucin 16 (2.2 fold ↑, conjunctiva) and reduced the activity of genes for S100 calcium binding proteins A8 and A9 (2.1 and 1.4 fold ↓, respectively, conjunctiva). Analysis of BeadChip raw data also revealed that DHT caused an 8.0 and 39.7 fold decrease in the mRNA levels of the small proline-rich proteins 2F and 2A, respectively, in meibomian gland epithelial cells.

Genes that demonstrated the greatest alterations in terms of statistical significance included those increased or decreased by DHT in immortalized human meibomian gland (aldo-keto reductase family 1, member C2 ↑, p<0.000001; DNA topoisomerase IIα ↓, p<0.000001), and conjunctival (uridine phosphorylase 1 ↑, p<0.000001; interferon, α-inducible protein 6 ↓, p<0.000001) epithelial cells.

The nature of androgen action on gene expression was predominantly cell-specific. Thus, 61.0 and 53.6% of upregulated genes, and 58.1 and 52.0% of downregulated genes, were unique to the meibomian gland and conjunctival epithelial cells, respectively. In addition, between 12.9 to

---

**Table 4. Opposite effects of DHT on gene expression in immortalized human meibomian gland and conjunctival epithelial cells.**

<table>
<thead>
<tr>
<th>Cell 1</th>
<th>Cell 2</th>
<th>C1 ↑, C2 ↓ (Genes)</th>
<th>%</th>
<th>C1 ↓, C2 ↑ (Genes)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meibomian</td>
<td>Conjunctiva</td>
<td>199</td>
<td>12.9–14.2</td>
<td>255</td>
<td>18.3–20.0</td>
</tr>
</tbody>
</table>

Log transformed data were analyzed and the total number of genes with GEO sequence identities in each category was then determined. Gene expression was significantly (p<0.05) up (↑)- or down (↓)-regulated by DHT in the specific cell type. Abbreviations: “C” stands for “cell.”

**Table 5. Effect of DHT on chromosomal gene expression in immortalized human meibomian gland and conjunctival epithelial cells.**

<table>
<thead>
<tr>
<th>Chromosome</th>
<th>Meibomian gland</th>
<th>DHT Genes ↑</th>
<th>Plac Genes ↑</th>
<th>DHT z-score</th>
<th>Plac z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>66</td>
<td>53</td>
<td>3.35</td>
<td>1.34</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>80</td>
<td>62</td>
<td>2.61</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>34</td>
<td>17</td>
<td>2.13</td>
<td>-1.44</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>73</td>
<td>95</td>
<td>-2.23</td>
<td>0.21</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>69</td>
<td>77</td>
<td>1.52</td>
<td>2.65</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>25</td>
<td>35</td>
<td>0.42</td>
<td>2.59</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>51</td>
<td>32</td>
<td>-0.08</td>
<td>-2.83</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>23</td>
<td>14</td>
<td>-1.23</td>
<td>-2.93</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chromosome</th>
<th>Conjunctiva</th>
<th>DHT Genes ↑</th>
<th>Plac Genes ↑</th>
<th>DHT z-score</th>
<th>Plac z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>66</td>
<td>45</td>
<td>4.08</td>
<td>-0.49</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>51</td>
<td>37</td>
<td>3.84</td>
<td>0.18</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>143</td>
<td>147</td>
<td>3.51</td>
<td>1.77</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>73</td>
<td>73</td>
<td>2.42</td>
<td>0.94</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>32</td>
<td>40</td>
<td>-2.33</td>
<td>-2.22</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>15</td>
<td>19</td>
<td>-2.39</td>
<td>-2.37</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>47</td>
<td>94</td>
<td>-2.57</td>
<td>1.77</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>24</td>
<td>46</td>
<td>-2.63</td>
<td>-0.19</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>35</td>
<td>60</td>
<td>-2.72</td>
<td>-0.51</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>34</td>
<td>82</td>
<td>-3.6</td>
<td>1.27</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>46</td>
<td>92</td>
<td>-1.53</td>
<td>3.15</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>51</td>
<td>85</td>
<td>-0.31</td>
<td>2.94</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>34</td>
<td>26</td>
<td>0.2</td>
<td>-2.13</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>64</td>
<td>44</td>
<td>1.51</td>
<td>-2.51</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>88</td>
<td>75</td>
<td>0.27</td>
<td>-2.76</td>
<td></td>
</tr>
</tbody>
</table>

Chromosomes with the highest and lowest z-scores were selected after analysis of log-transformed Illumina BeadChip data. A z-score is a statistical rating of the relative expression of genes, and shows how much they are over- or under-represented in a given gene list [59]. Positive z scores represent a greater number of genes meeting the criterion than is expected by chance, whereas negative z scores reflect fewer genes meeting the criterion than expected by chance [59]. Z-scores with values >2.0 or <-2.0 are quite significant and are highlighted in bold print. Terms: DHT Genes ↑ - number of genes upregulated in DHT-treated cells; Plac Genes ↑ - number of genes upregulated in placebo-treated cells; z-score - specific score for the upregulated genes in the DHT- and placebo-exposed cells.
20.0% of regulated genes were expressed in the opposite direction in these immortalized cells (Table 4).

The genes regulated by DHT were located on a variety of chromosomes. As shown in Table 5, the cellular pattern of this regulation showed some similarities and dissimilarities.

To confirm in part the Illumina BeadChip results, selected genes were analyzed by qPCR. This experimental approach verified the alterations of all tested genes (Table 6).

Androgen influence on the expression of gene ontologies and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in human ocular surface and meibomian gland epithelial cells:

Androgen administration had a significant impact on the biologic process, molecular function and cellular component gene ontologies, as well as on the KEGG pathways, in human ocular surface and meibomian gland epithelial cells.

As shown in Table 7, DHT significantly increased numerous ontologies in immortalized human meibomian gland epithelial cells, such as those associated with protein metabolism, signaling, tissue development, oxidoreductase and peptidase activities, intracellular organelles and peroxisomes. Treatment with DHT also stimulated 25 different ontologies (with ≥5 genes) concerned with lipid biosynthesis, homeostasis, transport and binding, as well as with cholesterol, fatty acid, phospholipid and steroid dynamics, as we recently reported [2]. In turn, DHT decreased ontologies linked to cell cycle, M phase, DNA metabolic processes, angiogenesis, innate immunity, RNA binding, and ribonucleoprotein complexes. These effects of DHT were paralleled by significant alterations in KEGG pathways. Androgen exposure upregulated pathways related to insulin, mTOR and peroxisome proliferator-activated receptor (PPAR) signaling, and downregulated those involved with the cell cycle, RNA transport and cancer (Table 8).

The influence of DHT on immortalized human conjunctival epithelial cells was quite different than that observed in human meibomian gland epithelial cells. As demonstrated in Table 9, DHT enhanced the expression of genes related to epithelium development, regeneration, wound healing, cell migration, Wnt receptor signaling, antioxidant activity and vacuoles, and reduced those associated with translation, RNA processing, mitotic cell cycle, immune response, JAK-STAT cascades, NADH dehydrogenase activity and ribosomes. In addition, androgen administration stimulated KEGG pathways linked to lysosomes, p53 signaling and endocytosis, and suppressed pathways involved with oxidative phosphorylation, the proteosome and RNA transport (Table 10).

Of interest, some ontologies were increased in both immortalized cell populations, regardless of treatment, such as cell death and apoptosis. In addition, there were ontologies that were decreased by androgens in both immortalized cells, including cellular component biogenesis, cellular location, innate immune response and nucleic acid metabolic processes. However, the majority of changes in gene ontologies and KEGG pathways appeared to be cell-specific.

### Table 6. Confirmation of selected Illumina BeadChip chip results by qPCR.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Illumina ratio</th>
<th>qPCR ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Meibomian Gland Epithelial Cells</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHT&gt;Placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keratin 16</td>
<td>2.4</td>
<td>5.7</td>
</tr>
<tr>
<td>Aldo-keto reductase family 1, member C2</td>
<td>2.6</td>
<td>1.7</td>
</tr>
<tr>
<td>Kallikrein-related peptidase 11</td>
<td>1.8</td>
<td>2.4</td>
</tr>
<tr>
<td><strong>Placebo&gt;DHT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDC28 protein kinase regulatory subunit 2</td>
<td>3.1</td>
<td>1.5</td>
</tr>
<tr>
<td>Minichromosome maintenance component 3</td>
<td>3.5</td>
<td>19.3</td>
</tr>
<tr>
<td>Leupaxin</td>
<td>3.1</td>
<td>57.8</td>
</tr>
<tr>
<td><strong>Conjunctival Epithelial Cells</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHT&gt;Placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laminin, α3</td>
<td>5.6</td>
<td>6.9</td>
</tr>
<tr>
<td>Plasminogen activator, urokinase</td>
<td>5.3</td>
<td>1.1</td>
</tr>
<tr>
<td>Uridine phosphorylase 1</td>
<td>4.2</td>
<td>2.7</td>
</tr>
<tr>
<td><strong>Placebo&gt;DHT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interferon, α-inducible protein 6</td>
<td>4.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Serum amyloid A1</td>
<td>5.7</td>
<td>3.1</td>
</tr>
<tr>
<td>EGF-containing fibulin-like extracellular matrix protein 1</td>
<td>4.9</td>
<td>2.5</td>
</tr>
</tbody>
</table>

The expression of designated genes, that were shown to be significantly altered in DHT-treated cells by using Illumina BeadChips, were re-examined with qPCR procedures. The qPCR data from meibomian gland cells were standardized to N (α) acetyltransferase B complex 50 and data from conjunctival cells were normalized to myosin, light chain 6, alkali, smooth muscle and non-muscle. Neither of the genes used for standardization responded to DHT exposure. The relative ratios of gene expression in 3 separate experiments are listed in the Illumina and qPCR “Ratio” columns.

<table>
<thead>
<tr>
<th>Ontology</th>
<th>DHT Genes ↑</th>
<th>Plac Genes ↑</th>
<th>DHT z-score</th>
<th>Plac z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biologic Process</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>programmed cell death</td>
<td>136</td>
<td>143</td>
<td>5.18</td>
<td>5.09</td>
</tr>
<tr>
<td>oxidation-reduction process</td>
<td>95</td>
<td>61</td>
<td>4.85</td>
<td>-1.42</td>
</tr>
<tr>
<td>protein metabolic process</td>
<td>280</td>
<td>278</td>
<td>4.35</td>
<td>2.85</td>
</tr>
<tr>
<td>purine ribonucleotide metabolic process</td>
<td>50</td>
<td>37</td>
<td>3.8</td>
<td>0.87</td>
</tr>
<tr>
<td>nerve growth factor receptor signaling pathway</td>
<td>28</td>
<td>22</td>
<td>3.38</td>
<td>1.44</td>
</tr>
<tr>
<td>response to hormone stimulus</td>
<td>61</td>
<td>48</td>
<td>3.36</td>
<td>0.7</td>
</tr>
<tr>
<td>regulation of signaling</td>
<td>132</td>
<td>106</td>
<td>3.14</td>
<td>-0.45</td>
</tr>
<tr>
<td>tissue development</td>
<td>80</td>
<td>69</td>
<td>2.58</td>
<td>0.46</td>
</tr>
<tr>
<td>cell cycle</td>
<td>75</td>
<td>202</td>
<td>-0.65</td>
<td>13.58</td>
</tr>
<tr>
<td>M phase</td>
<td>14</td>
<td>107</td>
<td>-3.29</td>
<td>13.34</td>
</tr>
<tr>
<td>DNA metabolic process</td>
<td>38</td>
<td>118</td>
<td>-0.87</td>
<td>11.17</td>
</tr>
<tr>
<td>organelle fission</td>
<td>12</td>
<td>81</td>
<td>-2.41</td>
<td>11.94</td>
</tr>
<tr>
<td>RNA processing</td>
<td>39</td>
<td>111</td>
<td>-0.49</td>
<td>10.47</td>
</tr>
<tr>
<td>angiogenesis</td>
<td>21</td>
<td>30</td>
<td>1.05</td>
<td>2.95</td>
</tr>
<tr>
<td>immune system process</td>
<td>99</td>
<td>122</td>
<td>0.86</td>
<td>2.66</td>
</tr>
<tr>
<td>innate immune response</td>
<td>27</td>
<td>41</td>
<td>-0.08</td>
<td>2.28</td>
</tr>
<tr>
<td>blood vessel development</td>
<td>30</td>
<td>35</td>
<td>1.49</td>
<td>2.15</td>
</tr>
<tr>
<td>regulation of cellular biosynthetic process</td>
<td>139</td>
<td>148</td>
<td>-2.24</td>
<td>-2.39</td>
</tr>
<tr>
<td>regulation of transcription</td>
<td>111</td>
<td>119</td>
<td>-2.26</td>
<td>-2.33</td>
</tr>
<tr>
<td>neurologic system process</td>
<td>59</td>
<td>33</td>
<td>-3.68</td>
<td>-7.15</td>
</tr>
<tr>
<td><strong>Molecular Function</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>protein binding</td>
<td>572</td>
<td>707</td>
<td>6.41</td>
<td>13.12</td>
</tr>
<tr>
<td>hydrogen ion transmembrane transporter activity</td>
<td>21</td>
<td>3</td>
<td>5.82</td>
<td>-1.58</td>
</tr>
<tr>
<td>oxido-reductase activity, acting on CH-OH group of donors</td>
<td>23</td>
<td>9</td>
<td>5.47</td>
<td>0.17</td>
</tr>
<tr>
<td>catalytic activity</td>
<td>423</td>
<td>403</td>
<td>5.11</td>
<td>2.27</td>
</tr>
<tr>
<td>translation factor activity, nucleic acid binding</td>
<td>16</td>
<td>8</td>
<td>4.47</td>
<td>0.82</td>
</tr>
<tr>
<td>peptidase activity</td>
<td>55</td>
<td>36</td>
<td>3.01</td>
<td>-0.63</td>
</tr>
<tr>
<td>RNA binding</td>
<td>61</td>
<td>127</td>
<td>1.12</td>
<td>10.03</td>
</tr>
<tr>
<td>nucleotide binding</td>
<td>164</td>
<td>243</td>
<td>1.32</td>
<td>7.58</td>
</tr>
<tr>
<td>ATPase activity</td>
<td>31</td>
<td>42</td>
<td>1.61</td>
<td>3.59</td>
</tr>
<tr>
<td>helicase activity</td>
<td>7</td>
<td>20</td>
<td>-0.89</td>
<td>3.2</td>
</tr>
<tr>
<td>ion channel activity</td>
<td>14</td>
<td>12</td>
<td>-2.51</td>
<td>-3.15</td>
</tr>
<tr>
<td>DNA binding</td>
<td>115</td>
<td>149</td>
<td>-2.82</td>
<td>-0.43</td>
</tr>
<tr>
<td>zinc ion binding</td>
<td>121</td>
<td>99</td>
<td>-0.68</td>
<td>-3.47</td>
</tr>
<tr>
<td>transporter activity</td>
<td>82</td>
<td>50</td>
<td>0.41</td>
<td>-3.94</td>
</tr>
<tr>
<td>transmembrane receptor activity</td>
<td>33</td>
<td>26</td>
<td>-5.76</td>
<td>-6.98</td>
</tr>
<tr>
<td><strong>Cellular Component</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vacuole</td>
<td>56</td>
<td>20</td>
<td>7.82</td>
<td>-0.56</td>
</tr>
<tr>
<td>lysosome</td>
<td>45</td>
<td>20</td>
<td>6.54</td>
<td>0.19</td>
</tr>
<tr>
<td>intracellular organelle</td>
<td>721</td>
<td>852</td>
<td>5.76</td>
<td>11.82</td>
</tr>
<tr>
<td>organelle membrane</td>
<td>191</td>
<td>152</td>
<td>5.26</td>
<td>0.86</td>
</tr>
<tr>
<td>endoplasmic reticulum</td>
<td>109</td>
<td>76</td>
<td>4.97</td>
<td>0.28</td>
</tr>
<tr>
<td>peroxisome</td>
<td>19</td>
<td>4</td>
<td>4.85</td>
<td>-1.23</td>
</tr>
<tr>
<td>nuclear part</td>
<td>165</td>
<td>335</td>
<td>-0.05</td>
<td>13.77</td>
</tr>
<tr>
<td>organelle lumen</td>
<td>195</td>
<td>344</td>
<td>1.62</td>
<td>13.26</td>
</tr>
<tr>
<td>ribonucleoprotein complex</td>
<td>37</td>
<td>104</td>
<td>0.52</td>
<td>12.01</td>
</tr>
<tr>
<td>chromosome</td>
<td>27</td>
<td>97</td>
<td>-1.62</td>
<td>10.08</td>
</tr>
<tr>
<td>spindle</td>
<td>9</td>
<td>47</td>
<td>-0.99</td>
<td>9.87</td>
</tr>
<tr>
<td>extracellular space</td>
<td>37</td>
<td>57</td>
<td>-2.23</td>
<td>0.31</td>
</tr>
<tr>
<td>cell junction</td>
<td>38</td>
<td>28</td>
<td>-0.19</td>
<td>-2.17</td>
</tr>
<tr>
<td>extracellular region</td>
<td>98</td>
<td>105</td>
<td>-3.36</td>
<td>-3.26</td>
</tr>
<tr>
<td>intrinsic to membrane</td>
<td>307</td>
<td>246</td>
<td>-2.55</td>
<td>-7.7</td>
</tr>
</tbody>
</table>

Designated ontologies were selected after the analyses of log-transformed data. Criteria for inclusion were an ontology containing ≥8 genes and having a z-score >2.0 or <-2.0. High and low values for the placebo (Plac) and DHT groups in specific ontologies are highlighted in bold print. Androgen administration also stimulated over 25 different ontologies related to lipid biosynthesis, homeostasis, transport and binding, as previously shown [2].
DISCUSSION

The present study demonstrates that androgen treatment significantly influences the expression of thousands of genes in immortalized human meibomian gland and conjunctival epithelial cells. The nature of this DHT action is predominantly cell-specific: some androgen responses are shared by both cell types, the majority are unique, and others are completely opposite. Depending upon the cell type, DHT exerts a significant effect on many gene ontologies and KEGG pathways, including those related to lipid dynamics, innate immunity, cell cycle, JAK-stat cascades, oxidative phosphorylation, the proteasome, and mTOR, Wnt and PPAR signaling. Our findings support our hypothesis that androgens regulate gene expression in human meibomian gland and conjunctival epithelial cells.

Our finding that the nature of DHT action on ocular surface and adnexal cells is predominantly cell-specific is not surprising. It is well established that androgen effects are not necessarily the same in different tissues. For example, androgens increase immunoglobulin A (IgA) and secretory component (SC) expression in the lacrimal gland, appear to have no influence on IgA or SC levels in salivary, respiratory, intestinal, uterine or bladder tissues, and actually decrease IgA amounts in the mammary gland [22,23]. In addition, we have found that testosterone induces a 7.8- to 13-fold increase in epidermal growth factor and nerve growth factor mRNA levels in the submandibular gland [24] but has no effect on these factors in the lacrimal gland (unpublished). Conversely, testosterone stimulates the expression of submandibular androgen-repressed protein (SMARP) in the lacrimal gland, but suppresses SMARP levels in the submandibular gland [25]. As another example, androgens promote the angiogenic activity of prostate epithelial cells, but reduce such activity by prostate stromal cells [26]. In effect, the nature of androgen influence is generally cell- and tissue-specific.

Androgen exposure caused a striking impact on gene expression in immortalized human meibomian gland epithelial cells. Most notable were the effects of DHT on lipids and keratin-related genes. Androgen treatment induced a significant increase in the activity of numerous genes associated with lipogenesis and cholesterogenesis [2]. This hormone response is analogous to the androgen influence on meibomian glands in vivo [27-30], wherein testosterone stimulates many genes linked to lipid metabolic pathways. Androgen administration also led to a 40 fold decrease in the mRNA level of small proline-rich protein 2A (SPPR2A). This gene, which is significantly upregulated in human meibomian gland dysfunction (MGD) [31], encodes a protein that promotes keratinization [32]; keratinization, in turn, is believed to be a primary cause of MGD and the consequent tear film hyperosmolarity and evaporative dry eye disease [3]. The SPPR2A gene is also significantly downregulated by androgens in meibomian glands of male and female mice [27,28]. These combined DHT effects, increasing lipogenesis and suppressing keratinization, may begin to explain how topical androgens enhance the synthesis and secretion of meibomian gland lipids, prolong the tear film breakup time and alleviate evaporative dry eye disease [32,33]. In addition, these DHT effects may account for why androgen insufficiency (e.g., during anti-androgen treatment, complete androgen insensitivity syndrome and/or aging) is associated with keratinization of the meibomian gland ductal epithelium (i.e., orifice metaplasia), altered meibum lipid profiles, and a reduced quality of meibomian gland secretions [34-38].

Androgen treatment also led to a significant change in the expression of many other genes in immortalized human meibomian gland epithelial cells, such as those associated with steroidogenesis, microbial protection, tissue development, oxidative stress, mTOR and PPAR signaling, cell cycle, innate immunity and angiogenesis. Androgen administration upregulated the mRNA levels of defensin β1, an antimicrobial peptide implicated in epithelial surface resistance to microbial colonization [39], as well as steroid-5α-reductase, α polypeptide 1, which catalyzes the
### Table 9. Effect of DHT on the expression of gene ontologies in human conjunctival epithelial cells.

<table>
<thead>
<tr>
<th>Ontology</th>
<th>DHT Genes ↑</th>
<th>Plac Genes ↑</th>
<th>DHT z-score</th>
<th>Plac z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biologic Process</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>apoptosis</td>
<td>141</td>
<td>152</td>
<td>6.33</td>
<td>4.91</td>
</tr>
<tr>
<td>response to stress</td>
<td>215</td>
<td>252</td>
<td>5.14</td>
<td>4.87</td>
</tr>
<tr>
<td>regulation of signal transduction</td>
<td>129</td>
<td>100</td>
<td>5.02</td>
<td>-0.55</td>
</tr>
<tr>
<td>epithelium development</td>
<td>50</td>
<td>33</td>
<td>4.95</td>
<td>0.25</td>
</tr>
<tr>
<td>nerve growth factor receptor signaling pathway</td>
<td>33</td>
<td>21</td>
<td>4.95</td>
<td>0.74</td>
</tr>
<tr>
<td>regeneration</td>
<td>18</td>
<td>9</td>
<td>4.87</td>
<td>0.51</td>
</tr>
<tr>
<td>wound healing</td>
<td>61</td>
<td>47</td>
<td>3.95</td>
<td>0.1</td>
</tr>
<tr>
<td>cell proliferation</td>
<td>106</td>
<td>144</td>
<td>3.17</td>
<td>5.15</td>
</tr>
<tr>
<td>cytokine production</td>
<td>32</td>
<td>30</td>
<td>2.99</td>
<td>1.36</td>
</tr>
<tr>
<td>cell migration</td>
<td>53</td>
<td>41</td>
<td>2.61</td>
<td>-0.81</td>
</tr>
<tr>
<td>cell adhesion</td>
<td>69</td>
<td>58</td>
<td>2.46</td>
<td>-0.79</td>
</tr>
<tr>
<td>MAPKKK cascade</td>
<td>35</td>
<td>19</td>
<td>2.59</td>
<td>-1.84</td>
</tr>
<tr>
<td>canonical Wnt receptor signaling pathway</td>
<td>15</td>
<td>14</td>
<td>2.32</td>
<td>1.18</td>
</tr>
<tr>
<td>toll-like receptor 4 signaling pathway</td>
<td>10</td>
<td>10</td>
<td>2.06</td>
<td>1.39</td>
</tr>
<tr>
<td>translation</td>
<td>27</td>
<td>109</td>
<td>-0.12</td>
<td>13.76</td>
</tr>
<tr>
<td>viral reproduction</td>
<td>19</td>
<td>103</td>
<td>-1.64</td>
<td>12.88</td>
</tr>
<tr>
<td>innate immune response</td>
<td>33</td>
<td>68</td>
<td>1.36</td>
<td>6.69</td>
</tr>
<tr>
<td>RNA processing</td>
<td>26</td>
<td>93</td>
<td>-2.41</td>
<td>6.63</td>
</tr>
<tr>
<td>cell cycle checkpoint</td>
<td>16</td>
<td>43</td>
<td>0.43</td>
<td>6.36</td>
</tr>
<tr>
<td>macromolecule metabolic process</td>
<td>411</td>
<td>583</td>
<td>0.7</td>
<td>5.9</td>
</tr>
<tr>
<td>gene expression</td>
<td>189</td>
<td>331</td>
<td>-2.00</td>
<td>5.18</td>
</tr>
<tr>
<td>immune response</td>
<td>69</td>
<td>103</td>
<td>1.66</td>
<td>4.27</td>
</tr>
<tr>
<td>mitotic cell cycle</td>
<td>54</td>
<td>82</td>
<td>1.65</td>
<td>4.2</td>
</tr>
<tr>
<td>JAK-STAT cascade</td>
<td>5</td>
<td>14</td>
<td>0.27</td>
<td>3.85</td>
</tr>
<tr>
<td>antigen processing and presentation</td>
<td>2</td>
<td>12</td>
<td>-0.98</td>
<td>3.53</td>
</tr>
<tr>
<td>system process</td>
<td>69</td>
<td>64</td>
<td>-4.59</td>
<td>-7.03</td>
</tr>
<tr>
<td>neurologic system process</td>
<td>57</td>
<td>40</td>
<td>-3.59</td>
<td>-7.13</td>
</tr>
<tr>
<td>regulation of transcription</td>
<td>105</td>
<td>117</td>
<td>-2.41</td>
<td>-3.68</td>
</tr>
<tr>
<td><strong>Molecular Function</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>protein binding</td>
<td>562</td>
<td>709</td>
<td>6.93</td>
<td>9.48</td>
</tr>
<tr>
<td>enzyme inhibitor activity</td>
<td>44</td>
<td>22</td>
<td>6.2</td>
<td>-0.08</td>
</tr>
<tr>
<td>SH3 domain binding</td>
<td>21</td>
<td>9</td>
<td>5.25</td>
<td>0.05</td>
</tr>
<tr>
<td>cell adhesion molecule binding</td>
<td>9</td>
<td>4</td>
<td>3.85</td>
<td>0.35</td>
</tr>
<tr>
<td>antioxidant activity</td>
<td>10</td>
<td>8</td>
<td>3.57</td>
<td>1.89</td>
</tr>
<tr>
<td>catalytic activity</td>
<td>374</td>
<td>450</td>
<td>2.59</td>
<td>2.73</td>
</tr>
<tr>
<td>translation initiation factor activity</td>
<td>7</td>
<td>11</td>
<td>2.09</td>
<td>3.63</td>
</tr>
<tr>
<td>voltage-gated ion channel activity</td>
<td>3</td>
<td>9</td>
<td>-2.8</td>
<td>-1.65</td>
</tr>
<tr>
<td>structural constituent of ribosome</td>
<td>5</td>
<td>69</td>
<td>-1.71</td>
<td>16.86</td>
</tr>
<tr>
<td>RNA binding</td>
<td>32</td>
<td>153</td>
<td>-2.89</td>
<td>12.32</td>
</tr>
<tr>
<td>threonine-type endopeptidase activity</td>
<td>0</td>
<td>14</td>
<td>-1.22</td>
<td>9.88</td>
</tr>
<tr>
<td>NADH dehydrogenase activity</td>
<td>0</td>
<td>16</td>
<td>-1.56</td>
<td>8.37</td>
</tr>
<tr>
<td>small GTPase regulator activity</td>
<td>22</td>
<td>8</td>
<td>0.82</td>
<td>-3.22</td>
</tr>
<tr>
<td>zinc ion binding</td>
<td>95</td>
<td>98</td>
<td>-2.84</td>
<td>-4.69</td>
</tr>
<tr>
<td>DNA binding</td>
<td>103</td>
<td>137</td>
<td>-3.53</td>
<td>-2.83</td>
</tr>
<tr>
<td>G-protein coupled receptor activity</td>
<td>8</td>
<td>13</td>
<td>-6.46</td>
<td>-6.7</td>
</tr>
<tr>
<td><strong>Cellular Component</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vacuole</td>
<td>43</td>
<td>32</td>
<td>5.27</td>
<td>1.48</td>
</tr>
<tr>
<td>cytoplasm</td>
<td>642</td>
<td>854</td>
<td>8.33</td>
<td>13.06</td>
</tr>
<tr>
<td>intracellular</td>
<td>792</td>
<td>1059</td>
<td>5.01</td>
<td>11.05</td>
</tr>
<tr>
<td>cell surface</td>
<td>43</td>
<td>30</td>
<td>3.99</td>
<td>0.03</td>
</tr>
<tr>
<td>lysosome</td>
<td>34</td>
<td>32</td>
<td>4.2</td>
<td>2.45</td>
</tr>
<tr>
<td>intracellular organelle part</td>
<td>389</td>
<td>592</td>
<td>2.42</td>
<td>9.7</td>
</tr>
<tr>
<td>organelle</td>
<td>631</td>
<td>924</td>
<td>2.15</td>
<td>11.22</td>
</tr>
<tr>
<td>intrinsic to membrane</td>
<td>293</td>
<td>281</td>
<td>-2.3</td>
<td>-7.61</td>
</tr>
<tr>
<td>ribonucleoprotein complex</td>
<td>18</td>
<td>128</td>
<td>-2.64</td>
<td>14.84</td>
</tr>
<tr>
<td>ribosome</td>
<td>6</td>
<td>68</td>
<td>-1.74</td>
<td>14.78</td>
</tr>
<tr>
<td>mitochondrion</td>
<td>80</td>
<td>224</td>
<td>-0.25</td>
<td>13.3</td>
</tr>
<tr>
<td>membrane part</td>
<td>361</td>
<td>366</td>
<td>-1.26</td>
<td>-6.2</td>
</tr>
</tbody>
</table>

Specific ontologies were selected after the analyses of log-transformed data. Criteria for inclusion in the Table were an ontology containing ≥8 genes and having a z-score >2.0 or <-2.0. High and low values for the placebo (Plac) and DHT groups in designated ontologies are highlighted in bold print.
conversion of testosterone into the more potent androgen, DHT [39]. This steroid regulation appears to be a form of feed-forward control exerted by DHT on its own biosynthesis [40]. Androgen increased the gene expression of leptin receptor, involved in the regulation of fat metabolism, glucose homeostasis, wound healing and the immune system [39]; FOXO1, a transcription factor that mediates cell responses to oxidative stress [39] and is known to interact with androgen receptors [41]; and stearoyl-CoA desaturase, an iron-containing enzyme that catalyzes the synthesis of unsaturated fatty acids. Testosterone enhances stearoyl-CoA desaturase mRNA levels in mouse male and female meibomian glands [27,28], and the targeted disruption of this rate-limiting enzyme causes meibomian gland atrophy [42]. Androgen exposure also increased ontologies and pathways related to peroxisomes, which are organelles involved in metabolism of fatty acids and other metabolites [39]; PPAR, which may promote tissue differentiation [43,44]; and mTOR, a serine/threonine protein kinase that may modulate cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription [39,45,46], and is also activated by androgens in the prostate [47]. Androgen administration downregulated genes related to cell cycle regulation (e.g., ubiquitin-conjugating enzyme E2C, cyclin-dependent kinase 1 and cyclin B2), innate immunity (e.g., chemokine (C-X-C motif) ligand 5 and thrombospondin 1) [39,48] and angiogenesis (e.g., thrombospondin 1). Thrombospondin 1 mRNA content is also decreased by androgens in the prostate, bladder and breast cancer cells [49-52]. Also notable was the DHT suppression of gene expression for matrix metalloproteinase 9, an enzyme that is increased in the tear film in dry eye and is known to promote corneal inflammation [53].

The effect of DHT on immortalized human conjunctival epithelial cells was quite different than that observed in human meibomian gland epithelial cells. For example, androgen administration enhanced the expression of genes involved in epithelium development, regeneration, wound healing and cell migration (e.g., matrix metalloproteinase, kallikrein-related peptidases 5, 6 & 11, cystatin E/M, laminin, α3), and suppressed those related to the immune response (e.g., chemokine (C-X-C motif) ligand 6, serpin peptidase inhibitor, clade B, member 4, complement component 1, r subcomponent, interferon-induced protein 44-like, interferon induced transmembrane protein, complement factor B) and mitotic cell cycle (e.g., septin 4, endothelin 1, F-box protein 6 and proteasome subunit, β type, 9). The decrease in immune-related gene activity may play a role in the reported androgen ability to alter the development of allergic conjunctivitis [5] and to attenuate the immune effect of lipopolysaccharide in both conjunctival and meibomian gland epithelial cells [54]. The downregulation of conjunctival genes associated with the cell cycle, which was also found in immortalized human meibomian gland epithelial cells, may reflect a hormone-induced bias toward cell differentiation as compared to proliferation. Androgens are also known to inhibit the cell cycle in other tissues [55-57].

Of particular interest was the DHT upregulation of mucin 16 (MUC16), and downregulation of mucin 1 (MUC1), gene expression in the conjunctival epithelial cells. These transmembrane mucins help to prevent pathogen penetration into the eye and to maintain a wet ocular surface phenotype [18]. The mucin gene intensities in our study were relatively low, especially for MUC16. This finding may reflect the fact that we cultured cells in serum-free media: exposure of conjunctival epithelial cells to serum, which leads to their stratification, has been reported to promote mucin expression [18]. It is possible that the lack of serum may also have influenced the nature of the MUC1 response to DHT. Thus, others have shown that androgen increases MUC1 expression when breast and prostate cell lines are cultured in serum [58]. This observation would be consistent with the decreased MUC1 levels found in the conjunctiva an individual with complete androgen insensitivity syndrome [12]. We are currently investigating whether the presence or absence of serum causes significant variations in the molecular biologic

<table>
<thead>
<tr>
<th>KEGG Pathway</th>
<th>DHT Genes ↑</th>
<th>Plac Genes ↑</th>
<th>DHT z-score</th>
<th>Plac z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial invasion of epithelial cells</td>
<td>16</td>
<td>5</td>
<td>5.02</td>
<td>−0.81</td>
</tr>
<tr>
<td>Lysosome</td>
<td>20</td>
<td>16</td>
<td>3.89</td>
<td>1.15</td>
</tr>
<tr>
<td>p53 signaling pathway</td>
<td>13</td>
<td>8</td>
<td>3.69</td>
<td>0.43</td>
</tr>
<tr>
<td>Axon guidance</td>
<td>18</td>
<td>3</td>
<td>2.89</td>
<td>−2.97</td>
</tr>
<tr>
<td>Endocytosis</td>
<td>25</td>
<td>17</td>
<td>2.78</td>
<td>−0.8</td>
</tr>
<tr>
<td>Ribosome</td>
<td>1</td>
<td>48</td>
<td>−2.25</td>
<td>13.98</td>
</tr>
<tr>
<td>Oxidative phosphorylation</td>
<td>7</td>
<td>38</td>
<td>−0.53</td>
<td>8.25</td>
</tr>
<tr>
<td>Proteasome</td>
<td>2</td>
<td>20</td>
<td>−0.73</td>
<td>7.76</td>
</tr>
<tr>
<td>Antigen processing and presentation</td>
<td>2</td>
<td>14</td>
<td>−1.35</td>
<td>3.04</td>
</tr>
<tr>
<td>RNA transport</td>
<td>8</td>
<td>24</td>
<td>−0.98</td>
<td>2.42</td>
</tr>
</tbody>
</table>

Pathways were chosen after the analysis of log-transformed data. The criterion for inclusion was a z-score >2.0 or <-2.0. High and low values for the placebo (Plac) and DHT groups in designated pathways are highlighted in bold print.
response of ocular surface and adnexal cells to androgen administration.

Ultimately, it is very important to demonstrate that cellular responses in vitro duplicate those in vivo. Such demonstrations, as we have recently done with androgens and the meibomian gland [2,27-31,34-38], may provide new and meaningful insight into the regulation of ocular surface cells in health and disease.

ACKNOWLEDGMENTS
The authors thank Dr. Ilene Gipson and Ms. Sandra Michaud (Boston, MA) for the immortalized human conjunctival epithelial cells. This research was supported by NIH grant R01 EY05612.

REFERENCES


55. Pradeep PK, Li X, Peegel H, Menon KM. Dihydrotestosterone inhibits granulosa cell proliferation by decreasing the cyclin D2 mRNA expression and cell cycle arrest at G1 phase. Endocrinology 2002; 143:2930-5. [PMID: 12130558]


